SLITRK5 is a cellular protein whose normal function appears to suppress bone formation and could be a potential new target for the treatment ofosteoporosis, according to a collaborative study conducted by Weill Cornell Medicine and NewYork-Presbyterian researchers.
Cells manifesting the SLITRK5 protein are marked with magenta (left) and a bone-forming osteoblast marker in green (center). These markers were observed in the cancellous bone in the medulla space (top) or on the outer layer covering the bone (bottom). The overlap between these two markers (right) shows that SLITRK5 is found in bone-forming osteoblasts but not in other cell types, helping to make SLITRK5 a target for skeletal disease treatment. Credit: Dr. Matthew Greenblatt and Dr. Jun Sun
There Research was published in the scientific journal Nature Communications.
Read Also
- Pandschirtal: North-east of Kabul, resistance group against Taliban arises Aug 19, 2021
- Egypt, Patrick Zaky remains in prison after more than 18 months of detention without trial Aug 22, 2021
- Mayenne: A pedestrian mowed down by a TGV, the rail traffic stopped Nov 21, 2022
- Cars | Incorrect guidance on car scrapping premiums has so far resulted in an additional bill of EUR 1.5 million for the state Jul 13, 2021
- The gendarmerie warns against theft at the “rendez-moi” Nov 23, 2022
- A renewed version of Holidays CTN Expo Fair May 25, 2022
- The National Rifle Association maintains its convention in Texas despite criticism of the massacre in an elementary school May 26, 2022